Article
Tocilizumab in Behçet's disease with refractory ocular and/or neurological involvement: response according to different clinical phenotypes.
Clinical and experimental rheumatology - 1 Jan 2000
Atienza-Mateo Belén, Beltrán Emma, Hernández-Garfella Marisa, Valls Pascual Elia, Martínez-Costa Lucía, Atanes Antonio, Moriano Clara, Cordero-Coma Miguel, Nolla Joan Miquel, Carrasco Cubero Carmen, Sánchez Martín Julio, Calvo-Río Vanesa, Demetrio Rosalía, Palmou-Fontana Natalia, González-Gay Miguel Ángel, Blanco Ricardo
Abstract excerpt
OBJECTIVES: Anti-IL6R tocilizumab (TCZ) therapy has proved to be useful in the treatment of refractory ocular and/or neurological involvement of Behçet's disease (BD). However, TCZ efficacy in other BD manifestations remains unclear. In this study we aimed to assess the efficacy of TCZ in the different clinical phenotypes of BD. METHODS: This is a multicentre study of BD patients treated with TCZ, due to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.